Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The possibility to detect the antibody to hepatitis C virus (HCV) has allowed to estimate the prevalence of this virus in patients with hepatic disease, mostly in those with hepatitis considered non-A non-B. Literature shows that HCV causes about 75% of cases of cryptogenic hepatitis and more than the 90% of post-transfusional hepatitis. Circumstantial evidence suggests the existence of a relationship between parenterally-transmitted non-A non-B hepatitis (PTH) and primary liver cancer (PLC). With the advent of anti-HCV, it is now possible to assess directly whether or not there is a relationship between PTH and PLC. So anti-HCV was looked for in the sera of 365 patients with cirrhosis prospectively followed-up for early detection the development of PLC, using an enzymatic immunoassay (ELISA Ortho DS). At baseline anti-HCV was detected in 221 patients (60%). During 5-39 month 53 patients developed PLC and anti-HCV was detected in 68% of them. The univariate analysis demonstrated that alcohol abuse, anti-HBs and anti-HBc were the only covariates that were significantly associated with an increase risk of developing PLC. When these factors were introduced in the step wise regression analysis, age and alcohol were found to be the only independent risk factors. The high prevalence of anti-HCV found in patients with cirrhosis and PLC suggests that HCV might play a role in this tumor; the frequent co-occurrence of HCV and HBV markers suggests that HCV-HBV coinfection might be pathogenically important; alcohol was the most important non-viral risk factor for PLC.
 ...
PMID:[Primary carcinoma of the liver and hepatitis C virus in Italy. A prospective study in patients with cirrhosis]. 256 1

The differential diagnosis of liver dysfunction after orthotopic liver transplantation can be difficult. Cytomegalovirus (CMV) hepatitis is one possibility. This report reviews our experience with 17 cases of pathologically proven CMV hepatitis following liver transplantation and demonstrates the need for percutaneous liver biopsies to establish the diagnosis. There were seven pediatric patients (ages 2-11 years, five males, two females) and ten adult patients (ages 17-53 years, eight males, two females). The most common symptoms were prolonged fever (15 patients, with a mean duration of 22 +/- 5.5 days), elevation in total bilirubin (14 patients), and elevation in liver enzymes (15 patients); all symptoms were also found in rejection. Leukopenia and thrombocytopenia, reported to frequently occur with CMV infection, were found in only three and five patients, respectively. Twelve patients with the above symptoms underwent percutaneous biopsy on one or more occasions to differentiate CMV hepatitis from rejection. The diagnosis was made at retransplantation in five patients. CMV hepatitis followed treatment for acute rejection in 14 patients and occurred without additional immunosuppression in three patients. All patients were maintained on cyclosporine and prednisone. Acute rejection episodes were treated with a 5-day tapering dose of steroids (17 courses in 12 patients), OKT3 monoclonal antibody [Ortho (4 patients)] antithymocyte globulin [Upjohn (2 patients)], and azathioprine (1 patient). CMV was isolated from urine (nine patients), blood (nine patients), throat (seven patients), lungs (two patients), and other organs (two patients). CMV was cultured from the liver biopsy specimens in five of the seven attempts in pediatric patients. When the diagnosis was confirmed in the absence of rejection, immunosuppression was routinely lowered. When rejection occurred concomitantly with CMV hepatitis, therapy had to be individualized. Retrospectively, three patients treated for rejection were noted at retransplantation to have only CMV hepatitis, and all three patients died. A high index of suspicion and the judicious use of liver biopsies is essential in order to differentiate CMV hepatitis from other causes of posttransplant liver dysfunction.
 ...
PMID:Occurrence of cytomegalovirus hepatitis in liver transplant patients. 283 33

Three commercially available 3rd-generation anti-HCV ELISAs (Abbott, Murex and Ortho) were evaluated in various serum panels: (A) blood donor samples (n = 403) with 1st- or 2nd-generation anti-HCV ELISA (various manufacturers) positive test results; (B) non-A, non-B hepatitis patients (n = 212); (C) multitransfused patients (n = 253); (D) serial dilutions of HCV confirmed (RIBA and PCR) positive blood donors (n = 24), and (E) first-time blood donors (n = 1,055). All samples of panels A, B and C were tested in PCR and RIBA-2. In panels A, B and C, 398 samples were HCV PCR positive: all were detected by Abbott and Ortho, and 397 (99.7%) by Murex. The sample missed by the Murex ELISA showed an isolated anti-C33c reactivity in RIBA-2. In panels A-C, 442 samples were RIBA-2 positive and all were detected by the 3 tests. With Probit analysis on results of panel D, no significant difference in sensitivity was observed between the 3 evaluated ELISAs. Specificities of Abbott, Murex and Ortho in 1,055 blood donors were 99.7, 99.3 and 99.9%, respectively (NS, chi 2). We conclude that the sensitivity and specificity of the 3 ELISAs are comparable although the C33c antigen in the Murex VK47 test should be improved.
 ...
PMID:Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. 748 86

The present study was designed to investigate the status of hepatitis C virus (HCV) infection and associated risk factors among Egyptian military recruits. The impact of HCV infection on liver function was also assessed. The sera of 726 military recruits were tested for HCV antibodies using second generation ELISA technique (Ortho). The overall prevalence was 330.4%. Considering the presence of hepatitis B and/or schistosomiasis infection, HCV antibodies were detected in 30.0% of HBsAg carriers, 36.8% of bilharzial patients and 48.8% of those with concomitant infections. Among individuals without schistosomiasis or HBV infection, the rate decreased to 22.5% positive with HCV. The present study indicated that parenteral exposure to the virus might be the most important route for acquiring infection, while blood transfusion had a very minor role. The study of the impact of HCV on liver functions revealed that a single infection with HCV only was associated with almost normal liver function tests. However, infection with more than one hepatitis virus revealed a greater impact on the liver function. Morbidity also increased when schistosomiasis infection was superimposed.
 ...
PMID:Prevalence, impact and risk factors of hepatitis C infection. 750 49

Until 1988 the putative agent of non-A/non-B (NANB) hepatitis had not been found. Research workers of the Chiron Corporation (California, USA) then identified, by "blind expression cloning", polypeptides which specifically bound antibodies present in sera of NANB-patients. A fusion polypeptide (C-100) was expressed in yeast. With the C-100 antigen prototype RIA and ELISA antibody tests were developed. Subsequently more polypeptides (C-200, C33c, C22) of the HCV-genome were added to the test system, resulting in second generation anti-HCV tests with increased sensitivity. For confirmation of HCV ELISA reactive samples, recombinant immunoblot (RIBA-2, Ortho; Innolia, Innogenetics) and dot immunoblot assays (Matrix, Abbott) were developed. Detection of HCV antigens has been hampered by the low virus titres in serum and the absence of free circulating viral antigen(s). However, with cDNA-PCR, applying primers of the highly (> 93% nucleotide homology) conserved 5' untranslated (5'UTR) region of the HCV genome, HCV-RNA in serum as well as in liver tissue can be detected. cDNA-PCR, although not yet commercially available, is useful to confirm HCV-viremia in patients. When chronic hepatitic C patients are treated with anti-viral drugs, the disappearance of HCV-RNA, as detected by PCR, is a measure of therapy response.
 ...
PMID:Testing for HCV markers. 751 61

Hepatitis C virus (HCV) is the chief aetiologic agent for the parenterally transmitted Non-A, Non-B (NANB) hepatitis. This preliminary study was done to determine the prevalence of anti-HCV in the blood donor population. Blood from 3,540 donors who donated blood to the Blood Services Centre, Hospital, Kuala Lumpur, from 25th August 1991 to 13th January 1992, was tested for anti-HCV using both the Ortho and Abbott 2nd Generation ELISA test kits. ELISA positive specimens were repeated twice but no confirmatory test was done. There were 53 out of 3,540 (1.49%) blood donors who were repeatedly reactive to anti-HCV by ELISA. We plan to do further tests to confirm the results, using RIBA-2 or Abbott Neutralising test. Twenty eight out of 1,713 (1.63%) Malays, 22 out of 1,373 (1.60%) Chinese and 2 out of 393 (0.50%) Indians had antibodies to HCV. There was no significant difference in prevalence in the different age groups. The majority of donors tested were males (3,511 out of 3,540) of which 53 (1.50%) were anti-HCV positive. Only 29 females were tested and all were negative. To determine infectivity of the anti-HCV positive cases we would like to introduce testing for RNA by polymerate chain reaction (PCR). Screening all donated blood for anti-HCV will decrease, but not totally eliminate, post-transfusion hepatitis.
 ...
PMID:Prevalence of hepatitis C virus antibodies in blood donors in Malaysia. 751 58

Hepatitis C virus (HCV), the main cause of non-A, non-B hepatitis in the United States and possibly in the world, is believed to be transmitted primarily through parenteral exposure. Many screening and supplemental tests are available to detect antibodies to HCV in serum. The ability to use commercial assays to detect antibodies to HCV in urine was investigated in this study. A total of 229 serum/urine matched samples were collected sequentially from forensic autopsy cases examined at the Office of the Chief Medical Examiner, State of Maryland. Testing was performed using the Ortho, Innogenetics, and Abbott second generation HCV screening tests and the INNO-LIA HCV Ab supplemental assay. Sample volumes were increased for urine testing. Forty-six of 229 serum samples were positive by screening and confirmed by supplemental tests. The urine samples produced positive results on 44-45 of the same 46 by screening tests and all 46 positives by the supplemental test. There were no false positive samples using urine when compared with the serum pairs. The one false negative sample using urine was still nonreactive when the urine volume was increased to 200 microliters using the screening tests. Generally, five times the serum volume was required for the screening tests to be optimal for urine samples. The urine samples were stored under different conditions prior to testing to determine the influence on antibody stability in urine.
 ...
PMID:Application of commercial assays to detect IgG antibodies to hepatitis C virus in urine: a pilot study from autopsy cases. 753 54

An enzyme-linked immunosorbent assay (ELISA) for the detection of HCV antibodies was established, using recombinant N-14 fusion protein, and compared with the results of Ortho's HCV antibody (C-100 Ab) test, in serum samples of 1848 normal blood donors and 248 patients with liver diseases. The following results were obtained. 1) N-14 antibodies and C-100 antibodies were detected in 25 (1.4%) and 17 (0.9%) out of 1848 normal blood donors, respectively. The detection rate was enhanced by 1% by using the N-14 test in addition to the C-100 kit. 2) The prevalence rate of anti-HCV in NANB liver diseases was 119 of 169 patients (70.4%) by the N-14 test and 114 of 169 patients (67.5%) by the C-100 test. 145 (85.8%) patients were positive by either one of the assays. The antibody in patients with chronic hepatitis tends to be detect in higher rate by the N-14 test than the C-100 test (p < 0.01). Reversely the latter could detect in higher rate than the former in patients with liver cirrhosis (p < 0.01). The detection rate of the antibody in patients with HCC was the same level by these two tests. By using both tests the detection rate was increased by 15-18%, up to totally 85.8% when compared with the rate obtained by testing either one of these tests. 3) Among 79 patients with liver diseases unrelated to HCV infections such as chronic hepatitis B and auto-immune hepatitis, 3 cases (3.8%) were detected by the N-14 test and 7 (8.9%) by the C-100 test, suggesting more strict specificity of the N-14 test. History of blood transfusion of the patients gave no difference in the results. In conclusion, the N-14 test for the detection of HCV infection seems to be specific and sensitive for the blood-screening, and the diagnosis of hepatitis C infection.
 ...
PMID:[Virological studies on the usefulness of anti-HCV ELISA assay using recombinant N-14 fusion protein in various liver diseases]. 768 26

Hepatitis C virus (HCV) antibodies were measured in 28 patients with auto-immune hepatitis type 1 using six different assay kits, three for C100-3 antibody and three for second generation HCV antibody, and two confirmatory tests to determine the prevalence of HCV infection in auto-immune hepatitis. These patients were confirmed to have human leucocyte antigen DR 4 or 2 which is susceptible to auto-immune hepatitis in Japanese. Of the 28 patients, four (14.3%) were positive for HCV antibody in all assays and reacted positively in at least one of the two confirmatory tests, indicating a true positive finding. Eight were positive for HCV antibody only by the Ortho ELISA kit and were negative in both confirmatory tests. The cut-off level for these results was low and became negative soon after the patients received corticosteroid treatment. Thus, these eight patients are presumed to be false-positive reactors. Hepatitis C virus RNA was detected in the serum of two of the four patients with HCV antibody and in none of 24 patients without HCV antibody. No significant difference was observed between the patients with and without HCV antibody in terms of clinical background, liver function tests and auto-antibodies. Our results showed that the prevalence of a past or present HCV infection in patients with auto-immune hepatitis in Japan is low; thus, auto-immune hepatitis is thought to be distinct from hepatitis type C. However, it is also suggested that HCV infection can potentially trigger auto-immune hepatitis.
 ...
PMID:Low prevalence of hepatitis C virus infection in patients with auto-immune hepatitis type 1. 769 9

The serodiagnosis of hepatitis C virus (HCV) infection was analyzed by a recombinant immunoblot assay (RIBA) with recombinant proteins encoded by the viral RNA isolated from our patients in Hamburg, Germany. The HCV RNA was amplified by PCR, and proteins encoded by the viral core and the NS3, NS4, and NS5 regions were expressed subsequently in Escherichia coli. The results obtained with our UKE RIBA were compared with the results of the Abbott HCV second-generation enzyme immunoassay (EIA). Serum samples from 270 patients, which were sent to us on the suspicion of HCV hepatitis and which were negative for hepatitis A virus and hepatitis B virus antibodies, were examined. In 227 cases (84.1%), there were identical positive (204 cases, 75.6%) or negative (23 cases, 8.5%) results in both tests. In 32 cases (11.9%), the reactive Abbott second-generation HCV EIA results could not be confirmed by the UKE RIBA and the HCV PCR. In follow-up studies conducted over 1 year, these results did not change. In three cases (1.1%), the UKE RIBA presented a positive result while the Abbott second-generation HCV EIA was negative. All three cases were positive in the HCV PCR and showed seroconversion in an HCV EIA 4 to 6 weeks later. In addition, 33 patient serum samples were examined by UKE RIBA in parallel with the Ortho RIBA 2.0. In three cases (9.1%), a positive Ortho RIBA 2.0 result could not be confirmed by the UKE RIBA and the HCV PCR. All three patients were free of complaints. The UKE RIBA showed also a smaller number of indeterminate results (3.0%) than the Ortho RIBA 2.0 (24.2%). This comparison study demonstrates that the commercially available HCV antibody tests should be further improved.
 ...
PMID:Study on reliability of commercially available hepatitis C virus antibody tests. 775 66


<< Previous 1 2 3 4 5 6 7 Next >>